Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPTIONS-05: H101 + Tislelizumab + Lenvatinib in Advanced Biliary Tract Cancer
NCT05823987Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- May 2023
- Primary completion
- Dec 2025
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 1
01
Overview
A Phase 2 trial of Oncorine in biliary tract cancer (BTC), sponsored by Fudan University. Started May 2023; status: recruiting.
02
Drugs
Oncorine
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT05823987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05823987.